GlassScriptPhysician profile
Alexa B Alter
NPI 1437797578
$7,613.04
in general payments reported to CMS, 2019-2025
24 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $83.31 · 2023: $4,447 · 2024: $2,074 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,286 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,286.49 |
| Education | $243.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $969.43 | 2023-2025 | Sotyktu, Sprycel |
| Abbvie INC. | $945.03 | 2023-2025 | |
| Incyte Corporation | $879.89 | 2023-2025 | Opzelura, Opzelura |
| Ucb, INC. | $827.22 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $819.48 | 2023-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $635.64 | 2023-2025 | |
| Dermavant Sciences, INC. | $437.76 | 2023-2024 | Vtama |
| Pfizer INC. | $412.24 | 2022-2024 | |
| Arcutis Biotherapeutics, INC. | $347.00 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $346.41 | 2023-2024 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $295.71 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $174.78 | 2023-2024 | Ilumya, Winlevi |
| Amgen INC. | $165.92 | 2023-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $105.20 | 2023-2025 | Jublia, Cabtreo |
| Botanix Sb INC | $47.89 | 2025 | Sofdra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $38.26 | 2023 | Ycanth |
| Galderma Laboratories, L.P. | $35.30 | 2023-2025 | |
| Lnhc, INC | $31.62 | 2025 | Zelsuvmi |
| Regeneron Healthcare Solutions, INC. | $21.42 | 2023 | Dupixent |
| Fresenius Kabi USA, LLC | $18.95 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $17.73 | 2025 | Valchlor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.25 | 2025 | Spevigo |
| Strata Skin Sciences, INC. | $13.61 | 2025 | Xtrac |
| Organon LLC | $10.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexa Alter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.